That PD-L1 could be a general prognostic marker was recently dismissed by a study in tumor samples from 982 patients collected from three trials of adjuvant therapy in early stage NSCLC, finding that PD-L1 expression was not predictive for survival benefit for adjuvant chemotherapy [43]. This evidence concerns the gene CD274 and neoplasm.